The First Case of Polymyositis Associated with Interferon Therapy.

Matsuya, Manabu; Abe, Takashi; Tosaka, Matsumi; Yonezawa, Kazuya; Ono, Akiko; Ikeda, Noriyasu; Yoshida, Yutaka; Akahonai, Yoshikazu; Kurokawa, Sei; Hayashi, Toshiaki; Yawata, Atsushi; Imai, Kohzoh; Matsumoto, Hiroyuki; Yachi, Akira

doi:10.2169/internalmedicine.33.806

Cited by 37 publications

(19 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Our findings validate previously published reports (10,16) suggesting that older age and African-American race are independent risk factors for RCC. Our findings thus corroborate our own clinical observations and seropositivity data, as well as frequent anecdotal reports in the literature that have strongly suggested an association between chronic HCV infection and RCC (11)(12)(13)(14)17).…”

Section: Discussionsupporting

confidence: 92%

Risk for Renal Cell Carcinoma in Chronic Hepatitis C Infection

Gordon

Moonka

Brown

et al. 2010

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

Background: Chronic infection with hepatitis C virus (HCV) confers increased risk for chronic renal disease, and numerous reports suggest an association with renal cell carcinoma (RCC), a cancer with rapidly rising global incidence. We sought to determine whether HCV infection confers an increased risk for developing RCC.Methods: With the use of administrative data from a large, integrated, and ethnically diverse healthcare system, we did a cohort study of 67,063 HCV-tested patients between 1997 and 2006 who were followed for the development of RCC until April 2008.Results: A search of the health system cancer registry for patients with the diagnosis of kidney cancer showed that RCC was diagnosed in 0.6% (17 of 3,057) of HCV-positive patients versus 0.3% (177 of 64,006) of HCV-negative patients. The mean age at RCC diagnosis was much younger in HCV-positive individuals (54 versus 63; P < 0.001). The univariate hazard ratio for RCC among HCV patients was 2.20 (95% confidence interval, 1.32-3.67; P = 0.0025). In a multivariate model that included the risk factors age, African-American race, male gender, and chronic kidney disease, the overall hazard ratio for RCC among HCV patients was 1.77 (95% confidence interval, 1.05-2.98; P = 0.0313).Conclusion: Chronic HCV infection confers a risk for the development of RCC. Impact: Clinicians should consider newly identified renal lesions in patients with chronic HCV infection with a heightened suspicion for neoplasm, and newly diagnosed cases of RCC may require more careful surveillance for the presence of HCV infection. Additional studies are required to confirm these findings and to explore potential mechanisms of oncogenesis. Cancer Epidemiol Biomarkers Prev; 19(4); 1066-73. ©2010 AACR.

show abstract

Section: Discussionsupporting

confidence: 92%

Risk for Renal Cell Carcinoma in Chronic Hepatitis C Infection

Gordon

Moonka

Brown

et al. 2010

Cancer Epidemiology, Biomarkers &Amp; Prevention

View full text Add to dashboard Cite

show abstract

“…However, the exact mechanisms whereby interferon contributes to the development of autoimmune disease are at the moment unclear (6,7). A few cases of polymyositis associated with interferon therapy have been described in the literature, and showed that after the discontinuation of interferon, the muscular weakness gradually recovered with or without immunosuppressive treatment (8,9). In addition, cardiotoxicity of interferon has been well-documented including cardiac arrhythmia, dilated cardiomyopathy, and ischemic heart disease as common presentations.…”

Section: Discussionmentioning

confidence: 99%

A Case of Polymyositis with Dilated Cardiomyopathy Associated with Interferon alpha Treatment for Hepatitis B

Lee

Kim

et al. 2002

J Korean Med Sci

View full text Add to dashboard Cite

Polymyositis is a rare complication of interferon alpha treatment as a result of immune-modulating role of the drug itself. In this case, interferon alpha induced polymyositis and cardiomyopathy is diagnosed in a 33-yr-old male patient with history of chronic hepatitis B. To treat hepatitis B, interferon alpha was administered until the proximal muscle weakness developed. Thereafter, sixteen cycles of immunoglobulin treatment (400 mg/kg) along with corticosteroids were instituted and led to an improvement in subjective symptoms with decreases in level of CPK and LDH. However, dilated cardiomyopathy has not improved in spite of the cessation of interferon treatment. Unlike the persistently elevated serum HBV DNA level, the serum ALT and AST levels have gradually decreased. Our case shows that clinical symptoms of polymyositis improved with steroid and immunoglobulin treatment without deterioration of the hepatitis B. To our knowledge, this is the first case of polymyositis associated with dilated cardiomyopathy after the administration of interferon in a patient with hepatitis B.

show abstract

“…Three cases of polymyositis linked to interferon treatment have been described in the literature, but as yet no cases of polymyositis occurring during the administration of a-interferon for malignant melanoma [6,10,11]. One case [10] described a patient who underwent treatment with c-interferon for renal cell carcinoma.…”

Section: Discussionmentioning

confidence: 99%

Polymyositis occurring during α-interferon treatment for malignant melanoma: a case report and review of the literature

Cirigliano

Rossa

Tavoni

et al. 1999

Rheumatology International

View full text Add to dashboard Cite

Polymyositis is a systemic autoimmune disorder characterised by proximal muscle weakness which most frequently involves the limbs, neck and trunk. Alpha interferon is an antiviral molecule with well-known immunomodulatory and antiproliferative effects, but its use is often associated with a variety of side effects, in particular autoimmune phenomena. We report the occurrence of polymyositis during treatment with alpha-interferon in a patient affected by malignant melanoma. Indirect evidence suggests that in this case the patient's myositis was not linked to her neoplasia, since the melanoma was confirmed to be in remission both at the time of the diagnosis of the muscle disease and again after more than one year of follow-up.

show abstract

The First Case of Polymyositis Associated with Interferon Therapy.

Cited by 37 publications

References 11 publications

Risk for Renal Cell Carcinoma in Chronic Hepatitis C Infection

Risk for Renal Cell Carcinoma in Chronic Hepatitis C Infection

A Case of Polymyositis with Dilated Cardiomyopathy Associated with Interferon alpha Treatment for Hepatitis B

Polymyositis occurring during α-interferon treatment for malignant melanoma: a case report and review of the literature

Contact Info

Product

Resources

About